[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,444,637
  • Shares Outstanding, K 191,586
  • Annual Sales, $ 15,360 K
  • Annual Income, $ -276,480 K
  • EBIT $ -303 M
  • EBITDA $ -302 M
  • 60-Month Beta 1.74
  • Price/Sales 156.09
  • Price/Cash Flow N/A
  • Price/Book 3.73

Options Overview Details

View History
  • Implied Volatility 86.35% (-23.11%)
  • Historical Volatility 84.21%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 759.75% on 09/12/25
  • IV Low 86.35% on 05/11/26
  • Expected Move (DTE 4) 1.13 (8.80%)
  • Put/Call Vol Ratio 22.94
  • Today's Volume 1,293
  • Volume Avg (30-Day) 1,321
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 32,052
  • Open Int (30-Day) 22,660
  • Expected Range 11.72 to 13.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.37
  • Low Estimate $-0.44
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.75 +9.36%
on 05/04/26
17.32 -25.81%
on 04/17/26
-2.09 (-13.99%)
since 04/10/26
3-Month
8.35 +53.89%
on 02/12/26
17.32 -25.81%
on 04/17/26
+3.70 (+40.44%)
since 02/11/26
52-Week
2.67 +381.26%
on 05/15/25
17.32 -25.81%
on 04/17/26
+9.85 (+328.33%)
since 05/09/25

Most Recent Stories

More News
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

FDA Breakthrough Therapy designation granted to  zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib...

RLAY : 12.85 (+0.71%)
Relay Therapeutics Reports While the Market Decides What Zovegalisib Really Means

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 4, 2026 Current Price $13.09 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 12.85 (+0.71%)
Relay Therapeutics Reports While Street Waits for Vascular Anomaly Data to Materialize

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 1, 2026 Current Price $12.72 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 12.85 (+0.71%)
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 12.85 (+0.71%)
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily...

RLAY : 12.85 (+0.71%)
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 12.85 (+0.71%)
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast...

RLAY : 12.85 (+0.71%)
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced...

RLAY : 12.85 (+0.71%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 12.85 (+0.71%)
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 12.85 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 13.62
2nd Resistance Point 13.32
1st Resistance Point 13.09
Last Price 12.85
1st Support Level 12.56
2nd Support Level 12.26
3rd Support Level 12.03

See More

52-Week High 17.32
Last Price 12.85
Fibonacci 61.8% 11.72
Fibonacci 50% 10.00
Fibonacci 38.2% 8.27
52-Week Low 2.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.